PARLIAMENTARY WRITTEN QUESTION
Sickle Cell Diseases: Analgesics (6 February 2023)
Question Asked
Asked by:
Janet Daby (Labour)
Answer
No specific assessment has been made by the NHS England National Specialised Commissioning Team on the potential merits of simplifying the administration of pain relief for Sickle Cell patients or, of increasing funding and staffing levels for sickle cell services. However the National Sickle Pain Group, a sub-group of the Specialised Commissioning Haemoglobinopathies Clinical Reference Group, has produced guidance for hospitals to improve the care for sickle cell patients presenting with acute sickle pain and are working on an associated acute pain audit to measure the time to first analgesia universally across England.
NHS England has launched an end to end sickle cell clinical pathway review led by the Health Inequalities Improvement team. The end to end clinical pathway for patients with Sickle Cell Disease is being reviewed to identify opportunities for delivering improvements. The review is at an early stage but has highlighted a number of opportunities to improve current services, including in relation to workforce, the digitalisation of care plans and general education of the public about the condition.
In addition, NHS England is undertaking an exercise to assess compliance of Specialist Haemoglobinopathy Teams and Haemoglobinopathy Co-ordinating Centres with the respective service specifications which are published on the Haemoglobinopathies Clinical Reference Group webpage.
Answered by:
Neil O'Brien (Conservative)
14 February 2023
Contains Parliamentary information licensed under the Open Parliament Licence v3.0.